Structure, dynamics, and functionality of tankyrase inhibitor-induced degradasomes

Molecular Cancer Research

Volumn 13, Issue 11, 2015, Pages 1487-1501

  Thorvaldsen, Tor Espen ^a,b   Pedersen, Nina Marie ^a,b   Wenzel, Eva M ^a,b   Schultz, Sebastian W ^a,b   Brech, Andreas ^a,b   Liestøl, Knut ^a,c   Waaler, Jo ^a   Krauss, Stefan ^a   Stenmark, Harald ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

B TRANSDUCING REPEAT CONTAINING PROTEIN; BETA CATENIN; CYTOPLASM PROTEIN; G 007LK; MULTIPROTEIN COMPLEX; PROTEIN; TANKYRASE INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG; AXIN; G007-LK; SULFONE; TANKYRASE; TNKS PROTEIN, HUMAN; TRIAZOLE DERIVATIVE;

ARTICLE; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DENSITY; ELECTRON; ELECTRON MICROSCOPY; FLUORESCENCE RECOVERY AFTER PHOTOBLEACHING; PRIORITY JOURNAL; WILD TYPE; WNT SIGNALING PATHWAY; ANTAGONISTS AND INHIBITORS; COLONIC NEOPLASMS; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

AXIN SIGNALING COMPLEX; CELL LINE, TUMOR; COLONIC NEOPLASMS; HUMANS; SULFONES; TANKYRASES; TRIAZOLES; WNT SIGNALING PATHWAY;

EID: 84947079246     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-15-0125     Document Type: Article

References (50)

1. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
2. Sethi JK, Vidal-Puig A. Wnt signalling and the control of cellular metabolism. Biochem J 2010;427:1-17.
3. Clevers H, Nusse R. Wnt/b-Catenin signaling and disease. Cell 2012;149:1192-205.
4. Valenta T, Hausmann G, Basler K. The many faces and functions of b-catenin. EMBO J 2012;31:2714-36.
5. Kimelman D, Xu W. b-catenin destruction complex: insights and questions from a structural perspective. Oncogene 2006;25:7482-91.
6. MacDonald BT, Tamai K, He X. Wnt/b-Catenin signaling: components, mechanisms, and diseases. Dev Cell 2009;17:9-26.
7. Metcalfe C, Bienz M. Inhibition of GSK3 by Wnt signalling-two contrasting models. J Cell Sci 2011;124:3537-44.
8. Li VS, Ng SS, Boersema PJ, Low TY, Karthaus WR, Gerlach JP, et al. Wnt signaling through inhibition of b-catenin degradation in an intact Axin1 complex. Cell 2012;149:1245-56.
9. Haikarainen T, Krauss S, Lehtio L. Tankyrases: structure, function and therapeutic implications in cancer. Curr Pharm Des 2014;20:6472-88.
10. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 2008;90:83-92.
11. Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 2009;461:614-20.
12. Lee E, Salic A, Krüger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS Biol 2003;1:e10.
13. Lehtiö L, Chi N-W, Krauss S. Tankyrases as drug targets. FEBS J 2013;280:3576-93.
14. Zhan P, Song YN, Itoh Y, Suzuki T, Liu X. Recent advances in the structure-based rational design of TNKSIs. Mol Bio Syst 2014;10:2783-99.
15. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, et al. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Res 2011;71:197-205.
16. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res 2012;72:2822-32.
17. de la Roche M, Ibrahim AEK, Mieszczanek J, Bienz M. LEF1 and B9L shield b-catenin from inactivation by Axin, desensitizing colorectal cancer cells to Tankyrase inhibitors. Cancer Res 2014;74:1495-505.
18. Mendoza-Topaz C, Mieszczanek J, Bienz M. The Adenomatous polyposis coli tumour suppressor is essential for Axin complex assembly and function and opposes Axin's interaction with Dishevelled. Open Biol 2011;1:110013.
19. Voronkov A, Holsworth DD, Waaler J, Wilson SR, Ekblad B, Perdreau-Dahl H, et al. Structural basis and SAR for G007-LK, a lead stage 1, 2, 4-Triazole based specific Tankyrase 1/2 inhibitor. J Med Chem 2013;56:3012-23.
20. Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, et al. A novel Tankyrase small-molecule inhibitor suppresses APC mutation-drivencolorectal tumor growth. Cancer Res 2013;73:3132-44.
21. Raiborg C, Grønvold Bache K, Mehlum A, Stang E, Stenmark H. HRS recruits clathrin to early endosomes. EMBO J 2001;20:5008-21.
22. Mu FT, Callaghan JM, Steele-Mortimer O, Stenmark H, Parton RG, Campbell PL, et al. EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. J Biol Chem 1995;270:13503-11.
23. Zhou P, Bogacki R, McReynolds L, Howley PM. Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins. Mol Cell 2000;6:751-56.
24. Johnson M, Sharma M, Jamieson C, Henderson JM, Mok MTS, Bendall L, et al. Regulation of b-catenin trafficking to the membrane in living cells. Cellular Signalling 2009;21:339-48.
25. Campeau E, Ruhl VE, Rodier F, Smith CL, Rahmberg BL, Fuss JO, et al. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 2009;4:e6529.
26. Sagona AP, Nezis IP, Pedersen NM, Liestol K, Poulton J, Rusten TE, et al. PtdIns (3) P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nat Cell Biol 2010;12:362-71.
27. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Meth 2012;9:676-82.
28. Raiborg C, Wenzel EM, Pedersen NM, Olsvik H, Schink KO, Schultz SW, et al. Repeated ER-endosome contacts promote endosome translocation and neurite outgrowth. Nature 2015;520:234-38.
29. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al. Activation of b-Catenin-Tcf signaling in colon cancer by mutations in b-Catenin or APC. Science 1997;275:1787-90.
30. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren B-Z, et al. Systematic comparison of constitutive promoters and the Doxycycline-inducible promoter. PLoS ONE 2010;5:e10611.
31. Stamos JL, Weis WI. The b-catenin destruction complex. Cold Spring Harb Perspect Biol 2013;5:a007898.
32. Sadot E, Conacci-Sorrell M, Zhurinsky J, Shnizer D, Lando Z, Zharhary D, et al. Regulation of S33/S37 phosphorylated b-catenin in normal and transformed cells. J Cell Sci 2002;115:2771-80.
33. Su Y, Fu C, Ishikawa S, Stella A, Kojima M, Shitoh K, et al. APC is essential for targeting phosphorylated b-catenin to the SCFb-TrCP ubiquitin ligase. Mol Cell 2008;32:652-61.
34. Hart M, Concordet JP, Lassot I, Albert I, del los Santos R, Durand H, et al. The F-box protein b-TrCP associates with phosphorylated b-catenin and regulates its activity in the cell. Curr Biol 1999;9:207-11.
35. Kim I-J, Kang HC, Park J-H, Shin Y, Ku J-L, Lim S-B, et al. Development and applications of a b-catenin oligonucleotide microarray: b-catenin mutations are dominantly found in the proximal colon cancers with microsatellite instability. Clin Cancer Res 2003;9:2920-5.
36. Reits EAJ, Neefjes JJ. From fixed to FRAP: measuring protein mobility and activity in living cells. Nat Cell Biol 2001;3:E145-7.
37. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
38. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 2013;13:11-26.
39. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan C-W, et al. Small moleculemediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7.
40. James RG, Davidson KC, Bosch KA, Biechele TL, Robin NC, Taylor RJ, et al. WIKI4, a novel inhibitor of Tankyrase and Wnt/b-catenin signaling. PLoS One 2012;7:e50457.
41. Shultz MD, Kirby CA, Stams T, Chin DN, Blank J, Charlat O, et al. [1, 2, 4]Triazol-3-ylsulfanylmethyl)-3-phenyl-[1, 2, 4]oxadiazoles: antagonists of the Wnt pathway that inhibit Tankyrases 1 and 2 via novel adenosine pocket binding. J Med Chem 2012;55:1127-36.
42. Callow MG, Tran H, Phu L, Lau T, Lee J, Sandoval WN, etal. Ubiquitinligase RNF146 regulates Tankyrase and Axintopromote Wnt signaling. PLoS One 2011;6:e22595.
43. Zhang Y, Liu S, Mickanin C, Feng Y, Charlat O, Michaud GA, et al. RNF146 is a poly (ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat Cell Biol 2011;13:623-9.
44. Yeh TY, Meyer TN, Schwesinger C, Tsun ZY, Lee RM, Chi NW. Tankyrase recruitment to the lateral membrane in polarized epithelial cells: regulation by cell-cell contact and protein poly (ADP-ribosyl) ation. Biochem J 2006;399:415-25.
45. Schwarz-Romond T, Merrifield C, Nichols BJ, Bienz M. The Wnt signalling effector Dishevelled forms dynamic protein assemblies rather than stable associations with cytoplasmic vesicles. J Cell Sci 2005;118:5269-77.
46. Schwarz-Romond T, Metcalfe C, Bienz M. Dynamic recruitment of axin by Dishevelled protein assemblies. J Cell Sci 2007;120:2402-12.
47. Munemitsu S, Albert I, Souza B, Rubinfeld B, Polakis P. Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein. Proc Natl Acad Sci U S A 1995;92:3046-50.
48. Behrens J, Jerchow B-A, Würtele M, Grimm J, Asbrand C, Wirtz R, et al. Functional interaction of an Axin homolog, Conductin, with b-catenin, APC, and GSK3b. Science 1998;280:596-9.
49. Faux MC, Coates JL, Catimel B, Cody S, Clayton AHA, Layton MJ, et al. Recruitment of adenomatous polyposis coli and b-catenin to axin-puncta. Oncogene 2008;27:5808-20.
50. De Rycker M, Price CM. Tankyrase polymerization iscontrolledbyits sterile alpha motif and poly (ADP-ribose) polymerase domains. Mol Cell Biol 2004;24:9802-12.